Skip to main content
. 2020 Oct 15;12(10):2991. doi: 10.3390/cancers12102991

Figure 1.

Figure 1

Peripheral blood KIR+ CD8+ T cell repertoire in healthy controls and solid cancer patients. (A) Frequency of mayor CD4+ and CD8+ T cell subsets and total CD56+CD3− NK cells in peripheral blood of healthy controls (n = 42) and cancer patients (80 melanomas, 80 bladder cancers and 89 ovarian cancers). (B) Frequency of KIR+ CD8+ T cell subsets in controls and cancer patients. (C,D) Frequency of KIR+ CD8+ T cell subsets in cancer patients according to the presence of the HLA-C2 or Bw4 ligands, respectively. ** p < 0.01, comparing KIR2DL1+ CD8+ T cells in HLA-C2 positive (C1C2 or C2C2) and negative (C1C1) cancer patients. Data represent frequency in total lymphocytes of different T and NK cells subsets.